Shield Therapeutics PLC STX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 1.35
- Day Range
- GBX 1.32–1.45
- 52-Week Range
- GBX 1.06–12.85
- Bid/Ask
- GBX 1.30 / GBX 1.40
- Market Cap
- GBX 1.08 Bil
- Volume/Avg
- 5.5 Mil / 6.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.95
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
Comparables
Valuation
|
Metric
|
STX
|
ZURA
|
CRNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.36 | 2.66 | 5.33 |
Price/Sales | 0.95 | — | 609.51 |
Price/Cash Flow | — | — | — |
Price/Earnings
STX
ZURA
CRNX
Financial Strength
|
Metric
|
STX
|
ZURA
|
CRNX
|
|---|---|---|---|
Quick Ratio | 2.64 | 4.92 | 12.92 |
Current Ratio | 2.95 | 4.97 | 13.07 |
Interest Coverage | −40.09 | — | — |
Quick Ratio
STX
ZURA
CRNX
Profitability
|
Metric
|
STX
|
ZURA
|
CRNX
|
|---|---|---|---|
Return on Assets (Normalized) | −76.58% | −71.08% | −38.81% |
Return on Equity (Normalized) | −117.12% | −139.85% | −44.79% |
Return on Invested Capital (Normalized) | −96.12% | −99.89% | −45.62% |
Return on Assets
STX
ZURA
CRNX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Bnqtgymjb | Yrhfl | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Tygvkldl | Bgnlxp | $70.8 Bil | |
HLN
| Haleon PLC ADR | Vgnrvdsd | Flkb | $38.2 Bil | |
VTRS
| Viatris Inc | Ctmbwszy | Vphs | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Jjgttync | Bvvz | $12.5 Bil | |
CTLT
| Catalent Inc | Snjlwbw | Ngszgv | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Bhzsxklt | Klyl | $4.3 Bil | |
CURLF
| Curaleaf Holdings Inc | Xxqhvkkd | Hst | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Vlmwptdc | Nmpgf | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Tkkbqfshs | Nhvs | $2.9 Bil |